News & Updates

First-line treatment with cemiplimab, either as monotherapy or in combination with platinum-based chemotherapy, provides clinical benefits to patients with unresectable locally advanced nonsmall cell lung cancer (NSCLC) who are not candidates for definitive concurrent chemoradiation, as shown by long-term follow-up data from EMPOWER-Lung studies.

Treatment with liposomal irinotecan in adults with relapsed small cell lung cancer (SCLC) achieves similar overall survival (OS) when compared with topotecan, but the former is associated with a higher overall response rate (ORR), according to the results of RESILIENT, randomized, open-label phase III trial.

In the 3-year analysis of the phase III CheckMate 816 trial, neoadjuvant nivolumab plus platinum doublet chemotherapy (nivo-chemo) continued to provide durable benefit for individuals with resectable non-small-cell lung cancer (NSCLC).

Adults with atopic dermatitis appear to have an increased risk of venous thromboembolism (VTE), although the risk difference relative to adults without AD is quite small, as reported in a study.

Faropenem, when used in combination with the other standard treatment drugs for the first-line treatment of tuberculosis (TB) infection, appears to be noninferior to ethambutol, with faropenem having the added benefit of lower frequency of adverse events (AEs), according to the results of an open-label study in China.

Uncertainty weighs heavily on managing tuberculosis (TB) infection in children, with multi-level factors influencing the decision-making regarding testing and treatment.